Please use this identifier to cite or link to this item:
Title: A short report on highlights of worldwide development of RIX4414: A Singaporean experience
Authors: Phua, K.B.
Quak, S.H. 
Emmanuel, S.
Goh, P.S.C.
Han, H.H.
Bock, H.L.
Hardt, K.
De, Vos B.
Keywords: Attenuated human rotavirus vaccine
Phase II clinical trial
Issue Date: 2006
Citation: Phua, K.B., Quak, S.H., Emmanuel, S., Goh, P.S.C., Han, H.H., Bock, H.L., Hardt, K., De, Vos B. (2006). A short report on highlights of worldwide development of RIX4414: A Singaporean experience. Vaccine 24 (18) : 3782-3783. ScholarBank@NUS Repository.
Abstract: In Singapore, we conducted a phase II randomized, double-blind, placebo-controlled dose ranging study using an attenuated human rotavirus vaccine, RIX4414. Altogether, 2464 healthy infants were recruited. Two oral doses of vaccine at 104.7, 105.2 or 106.1 ffu or placebo were administered with routine immunizations at 3 and 4 months of age. Seroconversion and 'vaccine take' in the vaccine groups 1-month post dose 2 varied from 76 to 91% and 98 to 100% respectively. Vaccine was well tolerated and did not interfere with response of concomitantly administered vaccines. © 2006 Elsevier Ltd. All rights reserved.
Source Title: Vaccine
ISSN: 0264410X
DOI: 10.1016/j.vaccine.2006.03.040
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.


checked on Jul 1, 2020


checked on Jul 1, 2020

Page view(s)

checked on Jun 30, 2020

Google ScholarTM



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.